RxDoctor Payments Data

Matthew Dvorchak, MD

Family Medicine · Hastings, PANPI 1902846405

Payments from drug & device makers

$5,185in general payments, 2019–2025

Across 395 payments — averaging $13.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$785
  • Novo Nordisk$710
  • AbbVie$641
  • GSK$480
  • Sanofi-aventis U.S. LLC$256
  • Johnson & Johnson$242
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$5,180100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,185 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$48,752
Medicare patients
142
Services billed
698

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban529$244,255
JardianceEmpagliflozin141$120,162
OzempicSemaglutide79$93,513
Trelegy ElliptaFluticasone/Umeclidin/Vilanter81$58,396
AustedoDeutetrabenazine20$47,366
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog49$46,290
CreonLipase/Protease/Amylase26$45,798
XareltoRivaroxaban71$33,865
LinzessLinaclotide46$30,970
TrulicityDulaglutide25$24,267
JanuviaSitagliptin Phosphate33$22,958
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog45$22,762
EntrestoSacubitril/Valsartan36$21,118
VraylarCariprazine Hcl11$15,217
Soliqua 100-33Insulin Glargine/Lixisenatide15$13,219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$785$244,255529 claims
Boehringer IngelheimJardiance, Tradjenta$32$127,133171 claims
Novo NordiskOzempic$710$93,51379 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arexvy, Shingrix$480$92,212175 claims
AbbVieCreon, Linzess, Vraylar$641$91,98583 claims
Teva Pharmaceuticals USA, Inc.Austedo$54$47,36620 claims
Johnson & JohnsonXarelto$242$33,86571 claims
Lilly USA, LLCTrulicity$202$24,26725 claims
MerckJanuvia$172$22,95833 claims
NovartisEntresto$159$21,11836 claims
AstraZenecaFarxiga, Brilinta$39$18,29555 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$256$13,21915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Hastings

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →